

To: [REDACTED] ([REDACTED]@minvws.nl]
From: [REDACTED]
Sent: Wed 3/11/2020 9:56:17 PM
Subject: RE: MSD Update [Confidential]
Received: Wed 3/11/2020 9:56:27 PM

Confidential

Dear [REDACTED]

Thank you for your response and confirmation, I look forward to meeting in person in the near future to progress this matter.

I am aware that we didn't follow up on our response to the COVID 19 Outbreak. If you should need any further information regarding our risk mitigation planning or R&D efforts to tackle the virus then please let me know.

Importantly I also wanted to share with you and Minister Bruins advanced notice of our planned announcement tomorrow. I would be grateful if you could inform the Minister is case questions reach him tomorrow.

As you already know, MSD is splitting off part of its product portfolio into a new independently listed global company. We are happy to announce that the U.S. headquarters of MSD has decided to name this spinoff Organon & Co.

Strengthening the Dutch pharma landscape

We strongly believe that this is an important development for the Dutch pharma landscape. The possible coming of Organon & Co. also matches with the ambition of the Minister to ensure the production and security of supply of medicines in the Netherlands. Organon & Co. it is anticipated will employ approximately 10,000 to 11,000 employees globally, of which over 10% may be located here in The Netherlands at our base in Oss city centre.

Organon & Co. will mainly focus on women's health. The focus of MSD will be on oncology, vaccines, hospital care and animal health.

MSD The Netherlands has yet to make a final decision on the proposed split. This decision is expected in May. Constructive talks with our works council are currently ongoing.

The name Organon & Co. will be formally put into effect as soon as the split is a fact. This is expected in the first half 2021.

We are very pleased with this name as it represents a strong brand with a rich heritage worldwide. Research shows that Organon is still a well-known name and associations with innovation in women's health are strong. A nearly 100-year old brand will be put back into use with this name. This makes us very proud.

Organon & Co. : Global Leader in Women's Health

Organon & Co. has the ambition to become the world's leader in women's health. Although major strides have been made in recent years with regard to women's health, the challenges of contraception, menopause and cardiovascular disease, for example, remain high across the world. With its unique experience, unprecedented innovative power and rapid use of scientific insights, Organon & Co. wants to take significant steps in improving women's health. In addition to women's health, the company also focuses on biosimilars, oncology and inflammatory diseases. Organon & Co. will also continue to develop medicines in the fields of dermatology, pain, respiratory and cardiovascular.

We will of course keep you updated about future developments. In the meantime, if you have any questions or concerns, please do not hesitate to reach out.

I look forward to meeting in person soon to progress our discussions

Yours sincerely

[REDACTED]

[REDACTED]

[REDACTED]

MSD BV

[Waarderweg 39](#), 2031 BN Haarlem, The Netherlands
 P.O. Box 581, 2003 PC Haarlem, The Netherlands

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

dubbel

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

5.1.2e

3 - 4

dubbel